Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity

Javitt, JC., Zlateva, GP., Earnshaw, S., Pleil, AM., Graham, C., Brogan, A., Shah, SN., & Adamis, AR. (2008). Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity. Value in Health, 11(4), 563-574.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

"Show Me the Energy Costs"
Article

Effectiveness of interventions for the remediation of lead-contaminated soil to prevent or reduce lead exposure-A systematic review
Article

Variation in estimates of heat-related mortality reduction due to tree cover in US cities
Article

Promoting reproducibility and increased collaboration in electric sector capacity expansion models with community benchmarking and intercomparison efforts